Upstream Bio Expects $207.4 Million To Fund Operations Through Its 2027 Trial Plans
Research spending rose to $36.6 million as verekitug moved toward pivotal asthma and nasal-polyp trials.
Upstream Bio, which is testing verekitug for severe inflammatory respiratory diseases, expects its $207.4 million in cash and short-term investments to finance planned operations through 2027. Its Tuesday earnings disclosure puts that funding horizon alongside plans to start pivotal trials early next year and receive results from ongoing studies later in 2027.
Research Costs Climb Before Pivotal Testing
Third-quarter research spending reached $36.6 million, compared with $33.0 million a year earlier. Upstream attributed the $3.6 million increase chiefly to personnel expenses, including stock compensation, and clinical work on verekitug.
The quarterly net loss widened to $41.2 million from $33.7 million. Administrative expenses were $7.2 million, versus $5.5 million; the company attributed that $1.7 million increase mainly to personnel expenses, including stock compensation, and professional fees.
Upstream Bio CEO Rand Sutherland said preparations for the planned trials had progressed, with “key clinical, regulatory, and manufacturing milestones now having been achieved.” The company plans to begin the pivotal asthma and nasal-polyp studies in the first quarter of 2027.
Quarterly Dosing Carries The Next Tests
Verekitug is an antibody aimed at the receptor for thymic stromal lymphopoietin, a protein involved in triggering inflammation. Upstream is developing it for severe asthma, chronic sinus inflammation with nasal polyps, and chronic obstructive pulmonary disease, or COPD, which restricts airflow from the lungs.
The pivotal studies will compare a 400-milligram dose every 12 weeks with placebo, using one study for each of the asthma and nasal-polyp indications. Upstream announced that strategy on September 1 following discussions with the FDA.
Earlier asthma results showed effectiveness similar to Tezspire, but the 24-week dose disappointed. The next pivotal tests therefore center on the shorter, quarterly regimen.
COPD And Longer-Term Asthma Results
The ongoing mid-stage COPD study has approximately 480 participants, with enrollment completion announced in August 2026. It compares verekitug with placebo in adults with moderate-to-severe disease, tests 12- and 24-week dosing schedules, and uses the annual rate of disease flare-ups as its main measure.
The asthma extension study has retained more than 90% of eligible participants from the preceding mid-stage study. It is assessing verekitug’s safety and effectiveness over longer treatment.
Upstream expects results from both the COPD trial and the asthma extension study in the second half of 2027—the same year through which it expects its current cash and investments to support planned operations.
Sources
- 8-K Filing — Upstream Bio, Inc. (UPB) — SEC EDGAR
- Exhibit upb-ex99_1.htm — Upstream Bio, Inc. 8-K exhibit — SEC EDGAR
- Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China | Fierce Biotech — fiercebiotech.com
- Upstream Bio Reports Third Quarter 2026 Financial Results — globenewswire.com
- 8-K filed 2026-09-01 — Upstream Bio, Inc. (earlier disclosure) — SEC EDGAR